Ken Griffin Beyond Spring Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.74 - $2.47 $21,228 - $30,134	-12,200 Reduced 69.71%	5,300 $12,000
Q2 2024 Aug 14, 2024	BUY	$1.76 - $3.6 $8,624 - $17,640	4,900 Added 38.89%	17,500 $42,000
Q1 2024 May 15, 2024	SELL	$0.85 - $3.63 $184,280 - $786,984	-216,800 Reduced 94.51%	12,600 $44,000
Q4 2023 Feb 14, 2024	SELL	$0.67 - $1.12 $4,891 - $8,176	-7,300 Reduced 3.08%	229,400 $206,000
Q3 2023 Nov 14, 2023	BUY	$0.75 - $1.16 $4,200 - $6,496	5,600 Added 2.42%	236,700 $189,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.39 $14,062 - $21,962	-15,800 Reduced 6.4%	231,100 $272,000
Q1 2023 May 15, 2023	SELL	$1.06 - $3.05 $13,992 - $40,260	-13,200 Reduced 5.07%	246,900 $276,000
Q4 2022 Feb 14, 2023	BUY	$0.56 - $2.61 $4,144 - $19,314	7,400 Added 2.93%	260,100 $488,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $16,005 - $29,865	-16,500 Reduced 6.13%	252,700 $250,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.